TW0006919004
TW0006919004
CALIWAY BIOPHARMACEUTICALS CO L
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 120.62B EUR | 155.33B EUR | 134.31B EUR | 240.71B EUR |
Enterprise Value | 116.6B EUR | 152.39B EUR | 131.78B EUR | 239.93B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | 14.43x | -- | -- | -- |
Price to Sales | 4,103.71x | 5,284.51x | 3,530.97x | 6,328.35x |
Price to Book | 13.09x | 16.87x | 14.35x | 25.58x |
EV/Revenue | 3,967.08x | 5,184.52x | 3,464.22x | 6,307.81x |
EV/EBITDA | -144.21x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -0.38% | -0.19% | -0.26% | -0.13% |